WO2015194923A1 - 엔테카비르를 유효성분으로 포함하는 약학 제제 및 이의 제조방법 - Google Patents
엔테카비르를 유효성분으로 포함하는 약학 제제 및 이의 제조방법 Download PDFInfo
- Publication number
- WO2015194923A1 WO2015194923A1 PCT/KR2015/006329 KR2015006329W WO2015194923A1 WO 2015194923 A1 WO2015194923 A1 WO 2015194923A1 KR 2015006329 W KR2015006329 W KR 2015006329W WO 2015194923 A1 WO2015194923 A1 WO 2015194923A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- entecavir
- pharmaceutical formulation
- antioxidant
- formulation
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Definitions
- the present invention relates to a pharmaceutical preparation comprising Entecavir (Entecavir) as an active ingredient, and a method for preparing the same, and to a method for maintaining entecavir stably in a pharmaceutical formulation containing water without hydrolysis. .
- Cyclopentyl] -6H-purin-6-one is an antiviral agent used as a treatment for hepatitis B virus infection, purine at 1S-position of cyclopentane, exomethylene at 2-position, 3R-position Hydroxymethyl and hydroxy at 4S-position.
- Phosphorylated in the form of entecavir triphosphate is activated and has a therapeutic effect on hepatitis B.
- Commercially available hepatitis B treatments comprise 0.5 mg or 1 mg of entecavir anhydride per unit dose.
- Entekavir has a water solubility of 2.4 mg / ml at pH 7.9, 25 ° C. (room temperature) and shows low stability against hydrolysis in the presence of moisture. Hydrolysis of entecavir leads to a decrease in efficacy, so it is essential to ensure the stability of entecavir to moisture.
- a method such as a waterproof coating or a sealed preservation is usually used to prevent contact with moisture present outside the formulation, and also minimizes the moisture in the formulation or other substances such as glycerin , Propylene glycol, alcohol, and the like).
- the problem to be solved by the present invention is to provide a method for stably maintaining entecavir in a pharmaceutical formulation containing a certain amount of water and a pharmaceutical formulation prepared by such a method.
- the problem to be solved by the present invention is to provide a pharmaceutical formulation of oral disintegrating (soluble) formulations that can be dissolved (or disintegrated) immediately upon oral administration as a pharmaceutical formulation comprising entecavir as an active ingredient to absorb the drug.
- the present invention is a pharmaceutical formulation comprising Entecavir (Entecavir) as an active ingredient, comprising at least one antioxidant to improve the stability of entecavir to water, pharmaceutical
- the formulations are directed to pharmaceutical formulations having a LOD (%) of at least 1% and less than 10% as measured according to USP 731 for 5 hours at 105 ° C.
- the present invention is a pharmaceutical formulation containing entecavir as an active ingredient, LOD (%) carried out in accordance with USP 731 for 4 hours at 105 °C, less than 10%, for improving the stability of entecavir to moisture It relates to at least one antioxidant use.
- the inventors have found that the addition of antioxidants can overcome the properties of entecavir, which is poorly stable to moisture, which is difficult to be stable and hydrolyzed by moisture in pharmaceutical formulations containing a certain amount of water.
- the present invention has been reached.
- LOD % performed according to USP 731 for 4 hours at 105 ° C. should be included at least 1%. Difficult to formulate into formulations (eg oral disintegrating films).
- an antioxidant has the excellent effect that entecavir can be stably maintained even in such excess moisture content formulations.
- the pharmaceutical preparations according to the present invention may include any pharmaceutical preparations containing entecavir as an active ingredient, and may include, for example, pharmaceutical preparations used for treating or preventing hepatitis B.
- 'stability against water' or 'water-stability' means stability to water, and in particular, stability to water included in a pharmaceutical formulation. It refers to the property that the physical and chemical properties of entecavir in the pharmaceutical formulation can be maintained unchanged, and particularly includes the property that entecavir can be maintained without hydrolysis by reacting with water.
- 'Entecavir' includes a pharmaceutically acceptable salt thereof, wherein the 'pharmaceutically acceptable salt' is a concentration that has a relatively nontoxic and harmless effective action in a patient.
- the 'pharmaceutically acceptable salt' is a concentration that has a relatively nontoxic and harmless effective action in a patient.
- organic or inorganic addition salt that does not reduce the beneficial efficacy of entecavir, such as organic acids and inorganic acids or non-toxic salts, and the like, hydrochloric acid, phosphoric acid, sulfuric acid.
- Nitric acid, tartaric acid, and the like, and organic acids include methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, and fumaric acid.
- Manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturic acid, article May be used tamsan, glutaric acid (glutaric acid), glucuronic acid (glucuronic acid), aspartic acid, ascorbic acid, carbonic acid, banil acid, hydroiodic acid (hydroiodic acid) or the like.
- Acid addition salts can be prepared by conventional methods such as dissolving the compound in an excess of aqueous acid solution and precipitating the salt using a water miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. Equivalent molar amounts of the compound and acid or alcohol in water can be heated and the mixture can then be evaporated to dryness or the precipitated salts can be suction filtered.
- a water miscible organic solvent such as methanol, ethanol, acetone or acetonitrile.
- the non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride , Acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suverate, sebacate, Fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitro benzoate, hydroxybenzoate, methoxybenzoate phthalate , Terephthalate, benzenesulfonate, toluenesulfonate, chlorobenz
- the pharmaceutical preparations according to the invention may comprise a therapeutically effective amount of entecavir.
- entecavir for example, the daily dose of entecavir, from 0.5 mg to 1 mg, may be subdivided.
- the 'antioxidant' has the same meaning as the 'antioxidant', and as a substance blocking the oxidation reaction, for example, propyl gallate, dry sodium sulfite, butylhydroxytoluene, sodium lauryl sulfate, retinol palmitate, riboflavin , Manganese, zinc oxide, sorbic acid, magnesium stearate, sodium citrate hydrate, citrate anhydride, citrate hydrate, diisopropyl adipic acid, ascorbic acid, sodium ascorbate, ascorbyl palmitate, sodium bisulfate, sodium decate , Oxybenzone, silicon dioxide, medium chain triglycerides, sodium bicarbonate, tocopherol, tocopherol acetate, benzophenone, butylhydroxyanisole, butylhydroxytoluene, sodium thiosulfate hydrate, sodium pyrosulfite, potassium pyrosulfite, D-manni
- the weight ratio of entecavir to antioxidant is 1000: 1 to 1: 100, preferably 100: 1 to 1:30, more preferably 50: 1 to 1: 10,40: 1 to 1 1: 10, most preferably 30: 1-1: 10.
- the weight ratio of entecavir to antioxidant is less than 1000: 1, it is difficult to secure the water-stability of entecavir in a large amount of water-containing preparations, and when the weight ratio of entecavir to antioxidant is greater than 1: 100, Preparation of pharmaceutical formulations is difficult.
- the time required for disintegration in the oral cavity is long, and thus it is not suitable as an oral disintegrant.
- antioxidants If butylhydroxytoluene, butylhydroxyanisole or mixtures thereof are used among antioxidants, the amount of antioxidant can be reduced to 1/30 or less compared to entecavir, thereby exhibiting sufficient water-stable effect. (eg film formulation).
- the water content of the pharmaceutical preparations according to the invention is at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, as measured by USP 731 for 105 hours at 105 ° C. , At least 7% and less than 10%.
- the water content of the pharmaceutical formulation is 105%, LOD (%) measured according to USP 731 for 4 hours, LOD (%) for solid formulations may be 1% or more and 7% or less, LOD (%) for film-like formulations May be 2% or more and 10% or less.
- the LOD (%) measurement condition, 105 °C, 4 hours is an optimal condition for confirming the moisture content in the pharmaceutical formulation, the content of the present invention is not limited to the above conditions, for example, may be measured for 105 °C, 5 hours. .
- the pharmaceutical preparations according to the invention may further comprise a pharmaceutically acceptable carrier which can typically be added to the pharmaceutical preparation.
- the pharmaceutically acceptable carrier includes additives such as excipients, disintegrants, binders, lubricants, emulsifiers, suspending agents, stabilizers, pH adjusting agents and the like commonly used in the pharmaceutical field, and if necessary, sweetening agents, flavoring agents and / or A coloring agent etc. can be further added.
- the excipients include microcrystalline cellulose, starch, silicon dioxide (SiO 2 ), sugar esters, Ludipress lactose, sucrose, maltose, fructose, sorbitol and the like.
- a mixture of lactose and silicon dioxide can be used.
- the amount of the excipient may be about 90% by weight or less based on the total weight of the pharmaceutical formulation, but is not limited thereto.
- the disintegrants include carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na), crospovidone, alginic acid and the like.
- the amount of the disintegrant may be in the range of 3-16% by weight based on the total weight of the pharmaceutical formulation, but is not limited thereto.
- the glidant may include stearic acid, magnesium stearate, zinc stearate, glyceryl behenate, glyceryl palmitostearate, talc, and the like, and may be used in an amount of about 3% by weight or less based on the total weight of the pharmaceutical preparation, but is not limited thereto. It doesn't happen.
- the pharmaceutical preparation according to the present invention may be used in addition to entecavir as an active ingredient as long as it does not inhibit the object of the present invention, and may include, for example, an additional anti-hepatitis B virus agent.
- the pharmaceutical preparations according to the invention can be administered in combination or alternately with additional anti-hepatitis B virus agents, for example interferon alpha-2b, peginterferon alpha-2a, lamivudine, telbibudine, recivir, emtricitabine, And may optionally be selected from clevudine, amtoxovir, valtorcitabine, tenofovir and adefovir.
- additional anti-hepatitis B virus agents for example interferon alpha-2b, peginterferon alpha-2a, lamivudine, telbibudine, recivir, emtricitabine, And may optionally be selected from clevudine, amtoxovir, valtorcitabine, tenofovir and adefovir.
- additional anti-hepatitis B virus agents for example interferon alpha-2b, peginterferon alpha-2a, lamivudine,
- the pharmaceutical preparations according to the invention can be formulated for oral administration, for example tablets, films, suspensions, granules, gels, pills, tinctures. ), Decoction, infusion, spirit, fluid, extract, elixir, extract, syrup, powder, fragrance aromatic water), lemonade (lemonade) and the like can be formulated in various forms.
- the tablet may be, for example, orally disintegrating tablets, mucoadhesive tablets, dispersible tablets, sublingual tablets, buccal tablets, chewing tablets Chewable tablets, dispensing tablets, multilayered tablets, press-coated tablets, effervescent tablets, solution tablets, etc. Can be. And those skilled in the art can be used to variously modify the various tablets as needed.
- formulations that disintegrate (dissolve) in the oral cavity i.e., disintegratable in the oral cavity, soluble in the oral cavity
- such as oral dispersible (dissolvable) formulations such as oral dissolution films, oral disintegrating tablets, suspensions, suspension tablets
- the formulation of the pharmaceutical preparation according to the present invention is preferably an oral dissolving film formulation. can do.
- the orally dissolving film may be used interchangeably with terms such as film, strip, orally disintegrating film, oral cavity, buccal mucosa, sublingual It refers to the dosage form to paste inside and take.
- the pharmaceutical formulation of the oral dispersible film formulation according to the present invention has the advantage that it can be taken without water.
- the present invention provides a pharmaceutical preparation method comprising Entecavir (Entecavir) as an active ingredient, comprising the steps of adding at least one antioxidant and entecavir; And drying the LOD (105%) according to USP 731 for 5 hours at 105 ° C., to have a moisture content of 1% or more.
- the LOD (%) carried out according to USP 731 for 4 hours by drying the oral disintegrating film prepared solution stabilized entecavir in water solvent by adding antioxidant Can provide an oral disintegrating film of 1% or more.
- entecavir by adding an antioxidant, entecavir can be stably maintained in a pharmaceutical formulation containing a certain amount or more of water, and thus, a pharmaceutical composition containing a certain amount or more of water, such as an orally disintegrating film formulation.
- a pharmaceutical formulation containing a certain amount or more of water such as an orally disintegrating film formulation.
- An enticavir-containing oral disintegrating film having improved stability to moisture was prepared by the method described below.
- Additives (components and their contents listed in Tables 1 and 3 below) were added to water as a solvent, followed by stirring to dissolve or disperse, and homogenized using a homogenizer (Ultra turrax T-25, IKA).
- a homogenizer Ultra turrax T-25, IKA.
- Add enticavir and dissolve it add a polymer (flurane, hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone, polyvinylalcohol-polyethyleneglycol copolymer, or a mixture thereof) and use the same homogenizer again.
- antioxidants antioxidants (antioxidants described in Tables 1 and 3 and their contents) dissolved in a suitable solvent (ethanol, methanol, acetone, mineral oil, or mixtures thereof) were added and homogenized separately.
- the gas in the film preparation solution was removed under vacuum conditions, coated on a PET (polyethylene terephthalate) film, and then dried at 60 to 80 ° C. to prepare a film
- HPLC Liquid Chromatography
- a film containing 1 mg of entecavir anhydride was received and placed in a 10 ml flask and mixed with the mobile phase. The mixture was placed in a centrifuge and centrifuged for 20 minutes. The centrifuge was filtered through a 0.2 ⁇ m filter (water soluble PTFE). As a result, a sample solution (0.1 mg / ml) was obtained.
- Oral soluble film was prepared by the preparation method of Example 1 described above in the components and contents shown in Table 1.
- LOD (%) is to dry the oral soluble film, based on the difference value of the weight of the oral soluble film before and after drying, can determine the content of water contained in the oral soluble film. For example, in Table 1 below, the LOD (%) of Example 1 is 7.8%, and 7.8% of water contained in the oral solution film is considered to be lost. When LOD (%) is less than 10.0%, it is considered to be suitable as an orally soluble film.
- Disintegration time relates to the time required for the disintegration (dissolution) of the oral dissolving film, and is considered to be suitable as an oral dissolving film when less than 1 minute.
- the LOD (%) of the oral disintegration (melting) formulations both showed 7.0% or more. That is, it was confirmed that the presence or absence of the antioxidant to the addition amount of the antioxidant does not affect the LOD (%).
- Examples 1-8 and 13-14 was found that disintegration time was less than 1 minute, while Examples 9-12 were longer than 1 minute to disintegrate oral disintegrating film. That is, it can be seen that there is a difference in the dissolution time of the oral disintegrating film according to the weight ratio of the antioxidant to entecavir.
- the stability test was conducted under harsh conditions (40 ⁇ 2 ° C., relative humidity 60 ⁇ 5%), and the pharmaceutical formulation was tested in a sealed aluminum foil container in order to block contact between external moisture and the formulation.
- Assay (%) relates to the amount of entecavir maintained in the pharmaceutical formulation
- Change amount (%) is the value of change in Assay (%) over time, through which the value of entecavir in the pharmaceutical formulation You can see if the amount of kabir changes. In this experiment, assay (%) was measured at week 0, week 4 and 8, and the difference between week 0 and week 8 assay (%) was described as the change amount (%).
- Total Impurities (%) are related to the amount of entecavir-derived analogues measured in pharmaceutical formulations, and Change amount (%) is the change in Total Impurities (%) over time. It can be seen that the change in the amount of entecavir flexible substances in the pharmaceutical formulation according to. In this experiment, Total Impurities (%) were measured at Week 0, Week 4, and Week 8, and the difference between Week 0 Total Impurities (%) and Week 8 Total Impurities (%) was described as Change amount (%).
- assay (%) was maintained at 97.0-103.0% during the storage period under severe conditions, it was found that little change in the change amount (%). That is, it was found that entecavir was maintained without being hydrolyzed by moisture during the storage period.
- Oral soluble film was prepared by the method of Example 1 described above in the components and contents shown in Table 3.
- LOD (%) is to dry the oral soluble film, based on the difference value of the weight of the oral soluble film before and after drying, can determine the content of water contained in the oral soluble film. When LOD (%) is less than 10.0%, it is considered to be suitable as an orally soluble film.
- the LOD (%) showed less than 10.0%.
- the LOD (%) of the oral disintegration (melting) formulation all showed more than 7.0%. That is, it was confirmed that the presence or absence of the antioxidant to the type of antioxidant does not affect the LOD (%).
- LOD (%) does not affect the entcavir moisture stability.
- the stability test was conducted under harsh conditions (40 ⁇ 2 ° C., relative humidity 60 ⁇ 5%), and the pharmaceutical formulation was tested in a sealed aluminum foil container in order to block contact between external moisture and the formulation.
- Assay (%) relates to the amount of entecavir maintained in the pharmaceutical formulation
- Change amount (%) is the value of change in Assay (%) over time, through which the value in the pharmaceutical formulation It can be seen if the amount of entecavir maintained is changing.
- assay (%) was measured at week 0, week 4 and 8, and the difference between week 0 and week 8 assay (%) was described as the change amount (%).
- Total Impurities (%) are related to the amount of entecavir-derived analogues measured in pharmaceutical formulations, and Change amount (%) is the change in Total Impurities (%) over time. It can be seen that the change in the amount of entecavir flexible substances in the pharmaceutical formulation according to. In this experiment, Total Impurities (%) were measured at Week 0, Week 4, and Week 8, and the difference between Week 0 Total Impurities (%) and Week 8 Total Impurities (%) was described as Change amount (%).
- the antioxidant weight ratio was 1:80 compared to entecavir, it showed excellent water-stability regardless of the type of antioxidant, but the antioxidant weight ratio was 1: 1 when the weight ratio of antioxidant to entecavir was used. In the case, excellent water-stability was shown only when butylhydroxytoluene and butylhydroxyanisole were used as antioxidants.
- the antioxidant weight ratio was 1:80 compared to entecavir, it showed excellent water-stability regardless of the type of antioxidant, but the antioxidant weight ratio was 1: 1 when the weight ratio of antioxidant to entecavir was used. In the case, excellent water-stability was shown only when butylhydroxytoluene and butylhydroxyanisole were used as antioxidants.
- the oral disintegrating tablet including entecavir was prepared by sizing into particles of a constant size, adding an excipient, a binder, a disintegrant, a lubricant, a sweetener, and the like, followed by mixing with a single tablet tablet.
- the dry weight-based moisture content of the orally disintegrating tablet was 105 ° C., and the LOD (%) measured according to USP 731 for 4 hours was 1% or more and less than 7%.
- the granules were prepared by dissolving entecavir, antioxidants and binders in a suitable solvent and then spraying a mixture of excipients and disintegrants on a fluid bed granulator. Excipients, sweeteners and flavoring agents were added to the granules prepared and mixed to prepare granules / powders containing entecavir.
- the dry weight moisture content of the granules / powders was 105%, LOD (%) measured according to USP 731 for 4 hours at least 1% and less than 7%.
- entecavir by adding an antioxidant, entecavir can be stably maintained in a pharmaceutical formulation containing a certain amount or more of water, and thus, a pharmaceutical composition containing a certain amount or more of water, such as an orally disintegrating film formulation.
- a pharmaceutical formulation containing a certain amount or more of water such as an orally disintegrating film formulation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
- 엔테카비르(Entecavir)를 유효성분으로 포함하는 약학 제제에 있어서,1 종 이상의 항산화제를 포함하고, 약학 제제는 105℃, 4시간 동안 USP 731에 따라 측정한 LOD(%)가 1% 이상 10% 미만인 것을 특징으로 하는 약학 제제.
- 제1항에 있어서, 상기 항산화제는 갈르산프로필, 건조아황산나트륨, 부틸히드록시톨루엔, 라우릴황산나트륨, 레티놀팔미테이트, 리보플라빈, 망초, 산화아연, 소르브산, 스테아르산마그네슘, 시트르산나트륨수화물, 시트르산무수물, 시트르산수화물, 아디핀산디이소프로필, 아스코르브산, 아스코르브산나트륨, 아스코르빌팔미테이트, 아황산수소나트륨, 에데트산나트륨수화물, 옥시벤존, 이산화규소, 중쇄트리글리세리드, 탄산수소나트륨, 토코페롤, 토코페롤아세테이트, 벤조페논, 부틸히드록시아니솔, 부틸히드록시톨루엔, 티오황산나트륨수화물, 피로아황산나트륨, 피로아황산칼륨, D-만니톨, D-소르비톨 및 L-시스테인염산염수화물로 이루어진 군에서 선택된 것을 특징으로 하는 약학 제제.
- 제2항에 있어서, 상기 항산화제는 부틸히드록시톨루엔, 부틸히드록시아니솔, 또는 이들의 혼합물인 것을 특징으로 하는 약학 제제.
- 제1항에 있어서, 상기 엔테카비르와 상기 항산화제의 중량비는 1000 : 1 ~ 1 : 100인 것을 특징으로 하는 약학 제제.
- 제1항에 있어서, 상기 엔테카비르와 상기 항산화제의 중량비는 30 : 1 ~ 1 : 10인 것을 특징으로 하는 약학 제제.
- 제1항에 있어서, 상기 약학 제제는 B형 간염 치료 또는 예방용 약학 제제인 것을 특징으로 하는 약학 제제.
- 제1항에 있어서, 상기 약학 제제는 구강붕해성필름 제형인 것을 특징으로 하는 약학 제제.
- 제7항에 있어서, 상기 구강붕해성필름 제형의 수분 함량은 105℃, 4시간 동안 USP 731에 따라 측정한 LOD(%)가 2% 이상 10% 미만인 특징으로 하는 약학 제제.
- 엔테카비르(Entecavir)를 유효성분으로 포함하는 약학 제제 제조방법에 있어서, 1종 이상의 항산화제 및 엔테카비르를 첨가하는 단계; 및 약학 제제가 105℃, 4시간 동안 USP 731에 따라 측정한 LOD(%)가 1% 이상 10% 미만인 수분 함량을 가지도록 건조하는 단계를 포함하는 것을 특징으로 하는 약학 제제 제조방법.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/320,446 US10045993B2 (en) | 2014-06-20 | 2015-06-22 | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor |
SG11201610636VA SG11201610636VA (en) | 2014-06-20 | 2015-06-22 | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor |
JP2016572806A JP6582000B2 (ja) | 2014-06-20 | 2015-06-22 | エンテカビルを有効成分として含む薬学製剤及びこの製造方法 |
CN201580044687.1A CN106573003B (zh) | 2014-06-20 | 2015-06-22 | 含有恩替卡韦作为活性成分的药物制剂及其制备方法 |
MYPI2016704731A MY185605A (en) | 2014-06-20 | 2015-06-22 | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor |
EP15809251.0A EP3158998A4 (en) | 2014-06-20 | 2015-06-22 | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor |
PH12016502544A PH12016502544B1 (en) | 2014-06-20 | 2016-12-20 | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0075457 | 2014-06-20 | ||
KR20140075457 | 2014-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015194923A1 true WO2015194923A1 (ko) | 2015-12-23 |
Family
ID=54935824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/006329 WO2015194923A1 (ko) | 2014-06-20 | 2015-06-22 | 엔테카비르를 유효성분으로 포함하는 약학 제제 및 이의 제조방법 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10045993B2 (ko) |
EP (1) | EP3158998A4 (ko) |
JP (1) | JP6582000B2 (ko) |
KR (1) | KR102435064B1 (ko) |
CN (1) | CN106573003B (ko) |
MY (1) | MY185605A (ko) |
PH (1) | PH12016502544B1 (ko) |
SG (1) | SG11201610636VA (ko) |
WO (1) | WO2015194923A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107714676B (zh) * | 2017-10-27 | 2020-05-15 | 苏州大学 | 恩替卡韦口腔速溶膜剂及其制备方法 |
EP4108243A4 (en) * | 2020-02-19 | 2024-04-17 | Sumitomo Pharma Co Ltd | TRANSDERMAL ABSORPTION PREPARATION |
CN114632073A (zh) * | 2020-12-15 | 2022-06-17 | 南京海辰药业股份有限公司 | 一种富马酸丙酚替诺福韦口腔速溶膜剂及其制备方法 |
CN113063881B (zh) * | 2021-04-15 | 2023-03-17 | 安徽万邦医药科技股份有限公司 | 一种恩替卡韦口服溶液有关物质分析方法 |
CN113730367B (zh) * | 2021-09-28 | 2022-12-02 | 海南海灵化学制药有限公司 | 一种恩替卡韦片的制备工艺 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101278938A (zh) * | 2008-03-20 | 2008-10-08 | 黑龙江加州国际投资咨询有限公司 | 泰诺福韦酯和恩替卡韦的复方制剂及其抗乙肝病毒的应用 |
KR20130029758A (ko) * | 2010-03-03 | 2013-03-25 | 코와 가부시키가이샤 | 불쾌한 맛을 갖는 약물을 함유하는 필름 제제 |
WO2013072937A2 (en) * | 2011-11-14 | 2013-05-23 | Hetero Research Foundation | Fast release solid oral compositions of entecavir |
WO2013114389A1 (en) * | 2011-12-21 | 2013-08-08 | Mylan Laboratories Limited. | Process for preparing solid oral formulations comprising low dose of entecavir |
WO2013177672A1 (en) * | 2012-05-31 | 2013-12-05 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1267880T2 (sl) * | 2000-02-29 | 2010-04-30 | Bristol Myers Squibb Co | Formulacija z nizko dozo entekavirja in uporaba |
TWI275392B (en) * | 2002-04-08 | 2007-03-11 | Bristol Myers Squibb Co | Low dose liquid entecavir formulations and use |
DE10224612A1 (de) * | 2002-06-04 | 2003-12-24 | Lohmann Therapie Syst Lts | Wirkstoffhaltige filmförmige Zubereitungen mit verbesserter chemischer Stabilität, und Verfahren zu deren Herstellung |
CN101756890A (zh) | 2008-11-25 | 2010-06-30 | 天津太平洋制药有限公司 | 一种含活性成分恩替卡韦经注射给药的制剂及其制备方法 |
US20110290694A1 (en) * | 2010-05-27 | 2011-12-01 | Monosol Rx, Llc | Oral film dosage form having indicia thereon |
KR20120100683A (ko) * | 2011-09-09 | 2012-09-12 | (주)차바이오앤디오스텍 | 안정한 경구용 속용 필름 제제 |
KR101285008B1 (ko) | 2012-04-18 | 2013-07-10 | 제일약품주식회사 | 저용량 엔테카비어의 경구투여 제제의 제조방법 |
KR102142539B1 (ko) * | 2012-12-11 | 2020-08-07 | 롯데정밀화학 주식회사 | 복합체 형성용 조성물, 이로부터 형성된 복합체 및 이를 포함하는 경구 섭취용 조성물 |
CN103181903B (zh) | 2012-12-21 | 2016-06-01 | 上海景峰制药股份有限公司 | 一种恩替卡韦的混合制粒方法 |
KR101462018B1 (ko) | 2013-04-01 | 2014-11-19 | 썬시스템즈(주) | 엔테카비르 함유 구강 붕해형 필름제제 |
CN103301071A (zh) | 2013-06-03 | 2013-09-18 | 北京阜康仁生物制药科技有限公司 | 一种稳定的恩替卡韦无糖型颗粒剂及其制备方法 |
-
2015
- 2015-06-22 US US15/320,446 patent/US10045993B2/en active Active
- 2015-06-22 WO PCT/KR2015/006329 patent/WO2015194923A1/ko active Application Filing
- 2015-06-22 EP EP15809251.0A patent/EP3158998A4/en not_active Withdrawn
- 2015-06-22 CN CN201580044687.1A patent/CN106573003B/zh active Active
- 2015-06-22 SG SG11201610636VA patent/SG11201610636VA/en unknown
- 2015-06-22 JP JP2016572806A patent/JP6582000B2/ja active Active
- 2015-06-22 KR KR1020150088703A patent/KR102435064B1/ko active IP Right Grant
- 2015-06-22 MY MYPI2016704731A patent/MY185605A/en unknown
-
2016
- 2016-12-20 PH PH12016502544A patent/PH12016502544B1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101278938A (zh) * | 2008-03-20 | 2008-10-08 | 黑龙江加州国际投资咨询有限公司 | 泰诺福韦酯和恩替卡韦的复方制剂及其抗乙肝病毒的应用 |
KR20130029758A (ko) * | 2010-03-03 | 2013-03-25 | 코와 가부시키가이샤 | 불쾌한 맛을 갖는 약물을 함유하는 필름 제제 |
WO2013072937A2 (en) * | 2011-11-14 | 2013-05-23 | Hetero Research Foundation | Fast release solid oral compositions of entecavir |
WO2013114389A1 (en) * | 2011-12-21 | 2013-08-08 | Mylan Laboratories Limited. | Process for preparing solid oral formulations comprising low dose of entecavir |
WO2013177672A1 (en) * | 2012-05-31 | 2013-12-05 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
Non-Patent Citations (1)
Title |
---|
See also references of EP3158998A4 * |
Also Published As
Publication number | Publication date |
---|---|
PH12016502544A1 (en) | 2017-04-10 |
EP3158998A1 (en) | 2017-04-26 |
EP3158998A4 (en) | 2018-02-14 |
KR20150145730A (ko) | 2015-12-30 |
SG11201610636VA (en) | 2017-01-27 |
US20170136025A1 (en) | 2017-05-18 |
JP2017522285A (ja) | 2017-08-10 |
CN106573003B (zh) | 2022-04-01 |
PH12016502544B1 (en) | 2017-04-10 |
KR102435064B1 (ko) | 2022-08-22 |
CN106573003A (zh) | 2017-04-19 |
JP6582000B2 (ja) | 2019-09-25 |
US10045993B2 (en) | 2018-08-14 |
MY185605A (en) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015194923A1 (ko) | 엔테카비르를 유효성분으로 포함하는 약학 제제 및 이의 제조방법 | |
EP2961383B1 (en) | Suspension for oral administration comprising amorphous tolvaptan | |
US11279682B2 (en) | Vortioxetine pyroglutamate | |
HU228389B1 (en) | Oral pharmaceutical preparation containing ibandronat | |
US10428086B2 (en) | Solvated crystal form of rifaximin, production, compositions and uses thereof | |
WO2019147094A1 (en) | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate | |
WO2013058450A1 (ko) | 안정화된 에페리손 의약 조성물 및 이를 함유하는 서방성 제제 | |
WO2022050670A1 (en) | Pharmaceutical compositions in a tablet form comprising omeprazole, esomeprazole, or a pharmaceutically acceptable salt thereof and processes for preparing the same | |
WO2021125797A1 (ko) | 올라파립의 용해도 및 생체이용율이 개선된 조성물 | |
WO2014163215A1 (ko) | 쓴 맛이 차폐된 약제학적 조성물 | |
WO2015130110A1 (ko) | 무정형 솔리페나신 또는 그의 염을 포함하는 안정성이 증가된 고체분산체 조성물 및 그 제조방법 | |
WO2022139223A1 (ko) | 나라트립탄을 포함하는 구강용해 필름 제형 | |
WO2022119300A1 (ko) | 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물 | |
WO2010008224A2 (ko) | 안정성이 개선된 암로디핀 속붕해성 정제 및 그의 제조 방법 | |
WO2018203636A1 (ko) | 수용해도 및 생체이용율이 개선된 조성물 | |
WO2014104844A1 (ko) | 불연속상과 연속상으로 이루어지는 응집단위를 포함하는 마이크로그래뉼 제형 | |
WO2021075926A1 (ko) | 프로톤 펌프 저해제 및 제산제를 포함하는 약학적 조성물 | |
WO2018004261A1 (ko) | 오셀타미비어 함유 경구용 고형제제 및 그 제조방법 | |
WO2013032310A1 (ko) | 메게스트롤 속붕해정 및 이의 제조 방법 | |
WO2018043850A1 (ko) | D-싸이클로세린의 약제학적 제형 및 이의 제조방법 | |
WO2023244062A1 (ko) | 신규한 구강용해산 조성물 | |
BR112019016802A2 (pt) | composição farmacêutica em comprimidos, e, comprimido | |
WO2022086238A1 (en) | Orally disintegrating tablet comprising benzimidazole derivative compound and preparation method thereof | |
WO2020091439A1 (ko) | 수니티닙을 함유하는 경구용 제제 및 그의 제조 방법 | |
TR2022013352A2 (tr) | Oral farmasöti̇k formülasyonlar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15809251 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016572806 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15320446 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2015809251 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015809251 Country of ref document: EP |